Contact

Jamie Lacey-Moreira, PressComm PR Principal & Founder

Are you ready to give your communications strategy a new perspective? The PressComm PR team works with life science and health care organizations, delivering a flexible, resource-leveraging communications program.

Please contact Jamie to let us know how we can help your organization:

Jamie Lacey-Moreira, Principal
PressComm PR, LLC
Ph: 410.299.3310
Email: jamielacey@presscommpr.com

News

December 4, 2019

Technical.ly Baltimore: UMB Licenses Technology to Y Combinator-backed Biotech Startup
A biotech startup that’s backed by Silicon Valley’s well-known Y Combinator accelerator has ties to Baltimore: GEn1E Lifesciences is working to commercialize a treatment for inflammatory and age-related diseases [Read More]
December 4, 2019

MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ’s Adoptive Cell Therapy Programs
Gaithersburg, MD and Cambridge, MA – December 4, 2019: MaxCyte, the global cell-based therapies and life sciences company, and KSQ Therapeutics, a biotechnology company using its [Read More]
December 3, 2019

GEn1E Lifesciences Granted Exclusive License for UMB Drug Portfolio Compound
PALO ALTO, Calif. and BALTIMORE, Dec. 3, 2019 /PRNewswire/ -- GEn1E Lifesciences Inc., a Y Combinator-backed biotech startup focused on curing inflammatory and age-related diseases, announced [Read More]

PressComm

Contact

Contact

Site Links

Social

About PressComm PR